Securities code: Ningbo Menovo Pharmaceutical Co.Ltd(603538) securities abbreviation: Ningbo Menovo Pharmaceutical Co.Ltd(603538) Announcement No.: 2022018 bond Code: 113618 bond abbreviation: Meinuo convertible bond
Ningbo Menovo Pharmaceutical Co.Ltd(603538)
Stock trading risk warning announcement
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Ningbo Menovo Pharmaceutical Co.Ltd(603538) (hereinafter referred to as “the company”) has accumulated more than 20% deviation from the closing price increase in three consecutive trading days on March 4, March 7 and March 8, 2022, which belongs to the abnormal fluctuation of stock trading stipulated in the trading rules of Shanghai Stock Exchange. The company has disclosed the announcement on abnormal fluctuation of Ningbo Menovo Pharmaceutical Co.Ltd(603538) Stock Trading (Announcement No. 2022017) on March 8, 2022.
On March 9, 2022, the company’s shares rose again. In view of the recent large fluctuation of the company’s share price, the relevant risks are as follows. Please pay attention to the secondary market risks, make rational decisions and invest prudently: first, there is no significant change in the company’s main business
The company is a pharmaceutical manufacturing enterprise specializing in the R & D, production and sales of characteristic APIs (including intermediates) and finished drugs. There are no major changes in the company’s internal and external operating environment that have not been disclosed through self inspection, but there are no other major changes in the company’s internal and external operating environment.
The company disclosed the third quarter report of 2021 on October 28, 2021. From January to September, 2021, the company realized an operating revenue of 9187033 million yuan, a year-on-year decrease of 3.18%; The net profit attributable to the shareholders of the listed company: 1353914 million yuan, a year-on-year decrease of 4.04%; Net profit attributable to shareholders of listed companies after deducting non recurring profits and losses: 1143872 million yuan, a year-on-year decrease of 10.62%.
2、 Risk tips for related businesses
(I) recently, some investors have paid attention to “whether the company involves SM1, SM2, T17 and pf-07321332 related intermediate products”. After verification by the company, the relevant business is explained as follows: at present, the company has realized commercial production of intermediate products SM1 and SM2, but the revenue accounts for a relatively small proportion, which does not have a significant impact on the company’s performance. At present, the orders undertaken by the company do not involve T17 and pf-07321332. The company is promoting the application for international MPP authorization, but it has not obtained relevant authorization as of the submission date of this announcement, and there is still great uncertainty about whether it can obtain authorization in the future.
(II) recently, some investors have paid attention to “whether the company has laid out assisted reproduction, and elderly care business industries”. After verification by the company, the relevant business conditions are explained as follows: the company’s main business does not involve assisted reproduction and elderly care industries. Ningbo Ningbo Menovo Pharmaceutical Co.Ltd(603538) Ruihe equity investment partnership (hereinafter referred to as “Ruihe fund”) with 32% of the company’s shares invested 7.5% of the equity of Jiangsu Meike Medical Technology Co., Ltd. (hereinafter referred to as “Meike medicine”). Neither Ruihe fund nor Meike medicine belong to the scope of the company’s consolidated statements, and the share participation ratio is small. Merck medical’s business scope involves gynecological testing and assisted reproduction, but the two businesses account for a low proportion and have little impact on the company’s performance.
3、 Relevant risk tips
(I) the deviation of the closing price increase of the company’s shares for four consecutive trading days on March 4, 2022, March 7, 2022, March 8, 2022 and March 9, 2022 amounted to 33.71%, and the short-term increase was higher than that of the same industry and the Shanghai stock index. Please pay attention to the trading risks in the secondary market, make rational decisions and invest prudently.
(II) the company solemnly reminds investors that the information disclosure media designated by the company is the website of Shanghai Stock Exchange (www.sse. Com. CN) According to China Securities News, Shanghai Securities News and securities times, the relevant information of the company shall be subject to the announcement published by the company in the above designated media. Please invest rationally and pay attention to investment risks.
It is hereby announced.
Ningbo Menovo Pharmaceutical Co.Ltd(603538) board of directors March 10, 2022
